Regeneron Pharmaceuticals Inc

US

REGN

Health Care

900.16 ₽

Current price

Buy
900.16 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    147 / 1361

  • Position in country

    2589 / 14179

  • Return on Assets, %

    12.7

    -40.3

  • Net income margin, %

    33.7

    -180

  • EBITDA margin, %

    32.4

    -168.2

  • Debt to Equity, %

    10.4

    3.2

  • Intangible assets and goodwill, %

    3.1

    0.2

  • Revenue CAGR 3Y, %

    15.5

    12.5

  • Total Equity change 1Y, %

    14.6

    -9

  • Revenue Y, % chg

    7.7

    0

  • P/E

    26

    31

  • P/BV

    3.8

    1.8

  • P/S

    7.5

    10.3

  • EV/S

    6.9

    7.5

  • EV/EBITDA

    19.5

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    17.1

    131.1

  • Forward P/E

    19.7

    21.4

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Biomarin Pharmaceutical Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    99301.5

  • Ticker

    REGN.O

  • ISIN

    US75886F1075

  • IPO date

    1991-04-02

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-05

  • Date fact. publication of reports

    2023-12-31

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: